A Phase II Study of Pazopanib With Oral Topotecan in Patients With Metastatic and Non-resectable Soft Tissue and Bone Sarcomas

Next Previous
Trial Profile

A Phase II Study of Pazopanib With Oral Topotecan in Patients With Metastatic and Non-resectable Soft Tissue and Bone Sarcomas

Recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Jan 2018

At a glance

  • Drugs Pazopanib (Primary) ; Topotecan (Primary)
  • Indications Liposarcoma; Osteosarcoma; Soft tissue sarcoma
  • Focus Therapeutic Use

    • Most Recent Events

    • 08 Jan 2018 Planned End Date changed from 1 Jul 2017 to 1 Jun 2020.
    • 08 Jan 2018 Planned primary completion date changed from 1 Jul 2017 to 1 Jul 2019.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top